Event-free survival (EFS) in patients with adverse-risk karyotypes classified by monosomal karyotype (MK), complex karyotype (CK), or monosomy 7 after exclusion of acute myeloid leukemia (AML) with either of the 2 marker lesions abnl(17p) or −5/5q−. (A) EFS at 2 years was 53% (95% confidence interval [CI], 30%-76%) in 19 patients with MK⁺ AML compared with 48% (95% CI, 36%-60%) in 76 patients with MK⁻ AML. (B) EFS at 2 years was 47% (95% CI, 31%-63%) in 38 patients with CK⁺ AML compared with 51% (95% CI, 37%-75%) in 57 patients with CK⁻ AML. See Figure 2 in the article by Middeke et al that begins on page 2521.¹